Showing results (91-100 of 285) with videos related to
Sort By:
Pageof 29
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|June 26, 2017
Therapeutic Targeting of Nuclear Export Inhibition in Lung CancerArjun Gupta, Jessica M Saltarski, Michael A White, et al.British Journal of Cancer|February 15, 2017
Revisiting a longstanding clinical trial exclusion criterion: impact of prior cancer in early-stage lung cancerSandi L Pruitt, Andrew L Laccetti, Lei Xuan, et al.Cancer|July 6, 2018
Statistical justification of expansion cohorts in phase 1 cancer trialsAli A Mokdad, Xian-Jin Xie, Hong Zhu, et al.Lung Cancer (Amsterdam, Netherlands)|February 27, 2017
Histologic transformation of EGFR mutant lung adenocarcinoma without exposure to EGFR inhibitionTri Le, Joseph Sailors, Dwight H Oliver, et al.Cancer Journal (Sudbury, Mass.)|December 14, 2011
Targeted therapies for lung cancer: clinical experience and novel agentsJill E Larsen, Tina Cascone, David E Gerber, et al.Clinical Drug Investigation|January 8, 2021
Prevalence and Significance of Potential Pharmacokinetic Drug-Drug Interactions Among Patients with Lung Cancer: Implications for Clinical TrialsSawsan Rashdan, Hui Yang, Tri Le, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|December 22, 2010
Predictors and impact of second-line chemotherapy for advanced non-small cell lung cancer in the United States: real-world considerations for maintenance therapyDavid E Gerber, Drew W Rasco, Phat Le, et al.Patient Education and Counseling|May 29, 2012
Patient comprehension and attitudes toward maintenance chemotherapy for lung cancerDavid E Gerber, Heidi A Hamann, Drew W Rasco, et al.Journal of the National Comprehensive Cancer Network : JNCCN|July 13, 2022
Potential Impact of Revised NCI Eligibility Criteria Guidance: Prior Malignancy Exclusion in Breast Cancer Clinical TrialsMatthew Perez, Caitlin C Murphy, Sandi L Pruitt, et al.Clinical Lung Cancer|July 27, 2013
Influence of medical comorbidities on the presentation and outcomes of stage I-III non-small-cell lung cancerDaniel H Ahn, Nishi Mehta, Jeffrey T Yorio, et al.Pageof 29